NCT07099651 Autosomal Dominant Spinocerebellar Ataxias and Social Cognition
| NCT ID | NCT07099651 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Angers |
| Condition | Autosomal Dominant Spinocerebellar Ataxia (SCA1, 2,3,6,7,27B) |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-12-09 |
| Primary Completion | 2028-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2025-12-09 with a primary completion date of 2028-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Spinocerebellar ataxias are a group of rare neurodegenerative diseases, clinically and genetically highly heterogeneous, with an estimated mean prevalence of 2.7 per 100,000 population. The term "spinocerebellar ataxia" or "SCA" is often used for ataxias of genetic origin of autosomal dominant transmission, which are the subject of this study. Recent studies of social cognition in patients with genetic cerebellar pathologies, and autosomal dominant spinocerebellar ataxia in particular, are still few and far between (around 15 studies), and seem to highlight impairment of basic emotion recognition and theory of mind skills. That said, data have very often been collected on very small samples of patients (sometimes in case study format). They also remain contradictory, including in the examination of the cerebellar anatomoclinical correlates of the deficits. Thus, the question arises as to whether patients with spinocerebellar ataxia also show impairments in emotion recognition and cognitive and affective theory of mind in more ecologically valid dynamic and interactive assessment situations.
Eligibility Criteria
Inclusion Criteria: For all participants: * Men or women aged 18 and over * At least 7 years' schooling (CEP level) * Ability to read, write and speak French * Signed informed consent to participate in the study For patients : \- With molecularly confirmed autosomal dominant spinocerebellar ataxia (SCA1, 2, 3, 6, 7, 27B) For controls: \- With no neurological pathology (questioning and neurological examination) Exclusion Criteria: For patients and controls: * Simultaneous participation in another protocol that may interfere with the measurement of the criteria of interest * Physical or cultural factors likely to interfere with test performance * History likely to interfere with cognition (stroke, cranioencephalic trauma, other neurodegenerative disease, epilepsy, learning disability, alcohol dependence syndrome, psychiatric disorders...) * Persons with contraindications to MRI scans * Pregnant, nursing or parturient women * Persons deprived of their liberty by judicial or administrative decision * Persons under compulsory psychiatric care * Persons subject to a legal protection measure * Persons unable to express their consent * Persons not affiliated to or not benefiting from a social security scheme (beneficiary or beneficiary entitled)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07099651 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Autosomal Dominant Spinocerebellar Ataxia (SCA1, 2,3,6,7,27B). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07099651 currently recruiting?
Yes, NCT07099651 is actively recruiting participants. Contact the research team at phallain@chu-angers.fr for enrollment information.
Where is the NCT07099651 trial being conducted?
This trial is being conducted at Angers, France.
Who is sponsoring the NCT07099651 clinical trial?
NCT07099651 is sponsored by University Hospital, Angers. The trial plans to enroll 160 participants.